Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
New Data Strengthen Case For RemeGen’s Telitacicept In gMG
‘Highest’ MG-ADL Response Rate
Apr 10 2025
•
By
Dexter Jie Yan
RemeGen has shown telitacicept's potenial as a an alternative to FcRn Inhibitors In gMG. • Source: Shutterstock
More from Clinical Trials
More from Rare Diseases